Previous 10 | Next 10 |
Today, we want to share our analysis of Sesen Bio (SESN) with you. The company's stock price has declined by more than 35% since mid-June after the release of secondary offering news. However, the company has a debt-free balance sheet with ~50% of its market cap in cash, and its lead drug has ...
Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Leslie L. Dan has retired from the Company's Board of Directors, effective July 16, 2019. With the retirement of Mr. Dan,...
Gainers: Melinta Therapeutics (NASDAQ: MLNT ) +180% . Arcturus Therapeutics (NASDAQ: ARCT ) +37% . Hebron Technology (NASDAQ: HEBT ) +26% . MYOS RENS Technology (NASDAQ: MYOS ) +22% . Armata Pharmaceuticals (NYSEMKT: ARMP ) +19% . AquaBounty Technologies (NASDAQ: AQB ) +19% . D...
Sesen Bio (NASDAQ: SESN ) -32% on pricing equity offering. More news on: Sesen Bio, Inc., Tonix Pharmaceuticals Holding Corp., Calithera Biosciences, Inc., Stocks on the move, Read more ...
Sesen Bio (NASDAQ: SESN ) has priced its public offering of 20.41M common shares and warrants to purchase same number of shares at $1.47/share and accompanying warrant, for gross proceeds of ~$30M. More news on: Sesen Bio, Inc., Healthcare stocks news, Stocks on the move, Read more ....
Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 20,410,000 shares of its common stock and warrants to purchase 20,410,000 s...
Sesen Bio (NASDAQ: SESN ) down 17.4% AH, as the company announces public offering of shares and warrants More news on: Sesen Bio, Inc., Healthcare stocks news, Read more ...
Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock and warrants to purchase shares o...
The following slide deck was published by Sesen Bio, Inc. in conjunction with this Read more ...
Sesen Bio (NASDAQ: SESN ) has completed a successful Type B Pre-BLA meeting regarding the approval path for Vicinium for the treatment of patients with Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC). More news on: Sesen Bio, Inc., Healthcare ...
News, Short Squeeze, Breakout and More Instantly...
Sesen Bio Inc. Company Name:
SESN Stock Symbol:
NASDAQ Market:
Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today anno...
Sesen Bio Board Believes the Pending Merger with Carisma is the Most Value-Maximizing Option for Stockholders Reiterates Support from Several of Sesen Bio’s Largest Stockholders and Two Leading Independent Proxy Advisors Sesen Bio Board Unanimously Recommends All St...
Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis’s Recommendations to Vote “FOR” Value Maximizing Merger on WHITE ...